CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
乳腺癌患者血脂水平与免疫微环境的关系：一项回顾性研究
英文原题：Relationship between serum lipid levels and the immune microenvironment in breast cancer patients: a retrospective study.
查看英文原题
Relationship between serum lipid levels and the immune microenvironment in breast cancer patients: a retrospective study.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
良好的血清脂质代谢控制可能改善绝经后 HR 阳性/HER2 阴性乳腺癌患者的肿瘤免疫微环境和预后。
研究思路结论见上方概要
用于治疗血脂异常的药物，尤其是他汀类药物，近期有报道称可抑制乳腺癌的生长和转移。然而，乳腺癌患者血脂控制的预测价值尚未得到充分讨论。此外，尽管免疫代谢是肿瘤免疫治疗中相对较新的方法，但脂质代谢与免疫状态之间的关系尚未得到充分记录。因此，我们研究了脂质代谢对抗肿瘤免疫反应和癌症预后的影响。
除导管原位癌患者外，共纳入938例接受根治性手术的患者。回顾性评估了血脂异常治疗或血清脂质水平与临床病理特征（包括预后）之间的相关性。此外，我们按乳腺癌内在亚型、绝经状态以及血脂异常治疗药物类型对这些结果进行了分层分析。同时，分别采用中性粒细胞与淋巴细胞比值（NLR）和TIL（肿瘤浸润淋巴细胞）（TILs）作为全身和局部免疫状态的指标。
在194例接受血脂异常治疗的患者中，使用降脂药物者与未使用者之间的无复发生存期（RFS）和总生存期（OS）无显著差异（log-rank检验分别为p = 0.775和p = 0.304）。在接受血脂异常治疗的绝经后、激素受体（HR）阳性/人表皮生长因子受体2（HER2）阴性乳腺癌患者中，血脂控制良好组的RFS显著优于控制不良组（log-rank检验p = 0.014），术后NLR更低（p = 0.012），切除组织中的TILs更高（p = 0.024）。多因素分析显示，术后血清血脂水平是复发的危险因素（风险比 = 4.722，95%置信区间1.006-22.161，p = 0.049）。
展开英文摘要原文
Therapeutic agents for dyslipidaemia, in particular statins, have been recently reported to suppress growth and metastasis of breast cancer. However, the predictive value of lipid control in breast cancer patients has not been discussed sufficiently. In addition, though immunometabolism is a relatively novel approach for tumour immunotherapy, the relationship between lipid metabolism and immune status has not been well documented. We therefore investigated the effects of lipid metabolism on antitumour immune response and cancer prognosis.
Except for patients with ductal carcinoma in situ, 938 patients treated with curative surgery were examined. The correlation between treatment for dyslipidaemia or serum lipid levels and clinicopathological features, including the prognosis, was evaluated retrospectively. Also, we stratified these results by intrinsic subtype of breast cancer, menopause, and type of therapeutic agents for dyslipidaemia. Moreover, neutrophil- to-lymphocyte ratio (NLR) and tumour-infiltrating lymphocytes (TILs) were used as indicators of systemic and local immune status, respectively.
Of 194 patients treated for dyslipidaemia, recurrence-free survival (RFS) and overall survival (OS) did not differ significantly between users of drugs for dyslipidaemia and non-users (p = 0.775 and p = 0.304, log-rank, respectively). Among postmenopausal, hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer patients treated for dyslipidaemia, the good serum lipid control group had significantly better RFS (p = 0.014, log-rank), lower postoperative NLR (p = 0.012), and higher TILs in resected tissues (p = 0.024) than the poor control group. Multivariate analysis showed that postoperative serum lipid levels were a risk factor for recurrence (hazard ratio = 4.722, 95% confidence interval 1.006-22.161, p = 0.049).
Good control of serum lipid metabolism may improve the tumour immune microenvironment and prognosis in postmenopausal HR-positive/HER2-negative breast cancer patients.
论文信息
- 作者
- Goto W、Kashiwagi S、Kamei Y、Watanabe C、Aomatsu N、Ikeda K、Ogawa Y、Hirakawa K
- 第一作者单位
- Department of Breast Surgical Oncology, Osaka City General Hospital, 2-13-22 Miyakojima-hondori, Miyakojima-ku, Osaka, 534-0021, Japan.Japan
- 通讯作者单位
- Department of Breast and Endocrine Surgery, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan. spqv9ke9@view.ocn.ne.jp.Japan
- 期刊
- BMC cancer2022 Feb 14
- 原文标识
- PubMed 35164691 · DOI 10.1186/s12885-022-09234-8
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →